• 생물정신의학
• /
• 제3권1호
• /
• pp.46-50
• /
• 1996

주요 우울장애 환자와 기분부전장애 환자에서 정상대조군과 비교하여 임파구에 isoproterenol 자극 후 cyclic AMP 생성반응에 차이가 있는지를 알아보고, 이 두 질환군에서 net cyclic AMP levels와 우울정도간의 상관성을 알아보고자 주요 우울장애군 8명, 기분부전장애군 9명, 정상대조군 10명을 대상으로 본 연구를 시행하였다. Cyclic AMP 농도는 방사면역 측정법 (radioimmunoassay)으로 측정하였다. 결과를 요약하연 다음과 같다. 1) HDRS 정수상 주요 우울장애군이 기분부전장애군보다 유의하게 우울정도가 높았다. 2) Isoproterenol 자극전 basal cyclic AMP levels는 정상대조군, 주요 우울장애군, 기분부전장애군간에 차이가 없었다. 3) Isoproterenol $10^{-5}mol/L$ 자극후 net cyclic AMP levels는 정상대조군 주요 우울장애군, 기분부전장애군간에 유의한 차이를 보였다. 4) 주요 우울장애군에서 isoproterenol $10^{-5}mol/L$ 자극후 net cyclic AMP levels와 HDRS 점수간에 유의한 역상관관계를 보였으나, 기분부전장애군에서는 상관관계를 보이지 않았다. 이상의 결과로 저자들은 기분부전장애가 임상적으로는 주요 우울장애의 우울정도가 경미한 한 형태로 보이지만 생물학적으로는 이들 두 질환이 다른 질환일 수 있다고 생각하였다.

• 생물정신의학
• /
• 제14권1호
• /
• pp.14-20
• /
• 2007

Objectives : The diagnosis of depression is based on a highly variable set of symptoms. Therefore, depression should not be viewed as a single disease, but a heterogenous syndrome comprised of different pathophysiologies. There are several subtypes of depression which were already incorporated in DSM-IV. This article provides a systematic review of pharmacological treatments of two recognized subtypes of depression-dysthymic disorder and atypical depression. Methods : Systematic search of relevant literatures on dysthymic disorder and atypical depression was performed by proposed search strategy of the Clinical Research Center for Depression of Korean Health 21 R&D Project. All identified literatures were carefully reviewed and classified according to SIGN grading system and summarized in a narrative manner. Results : For the treatment of dysthymic disorder and atypical depression, selective serotonin reuptake inhibitors( SSRIs) and moclobemide have more evidence than the other antidepressants. SSRIs and moclobemide showed superior tolerability than tricyclic antidepressants. Conclusions : The authors proposed treatment recommendations for dysthymic disorder and atypical depression by the methods of evidence-based medicine(EBM). However, guideline developing methods of EBM also have several inevitable limitations. Therefore, in the absence of clear and significant differences in efficacy, the choice of medication must be individualized for a particular patient based on psychiatrist's own clinical decision.

• 생물정신의학
• /
• 제9권2호
• /
• pp.103-111
• /
• 2002

Neurocognitive research focusing on cognitive deficits in Depression has resulted in several important but yet potentially contradictory findings. Much literature documents the presence of significant neurocognitive impairments in depressive patients. Studies have shown that dysthymic disorder patients demonstrate a diffuse pattern of cognitive impairment which is frequently indistinguishable from that of focal braindamaged patients. Some reports have suggested that there is a focal pattern of deficit, such as anterior cingulate dysfunction, frontal lobe impairment, or dysfunction of the temporal-limbic cortex. The aim of this study is to evaluate the neurocognitive functions in dysthymic disorder patients, and to compare the functions with those of major depressive disorder patients. The subjects are 17 dysthymic disorder patients. And their neurocognitive functions are compared with those of 23 major depressive episode patients. Patients with a history of neurologic disease, alcohol dependence, substance abuse and mental retardation are excluded. They are assessed with a part of Vienna Test System which is computerized neurocognitive function tests and can evaluate attention, eductive ability, reproductive ability, visuoperceptual analysis, vigilance, visual immediate memory, the speed of information-processing, judgement, and fine motor coordinations. There are no other specific difference between two groups, except the result of cognitrone test. This study provides information about the neurocognitive functions and some difference between major depressive disorder patients and carefully diagnosed dysthymic disorder patients.

• 생물정신의학
• /
• 제6권1호
• /
• pp.96-101
• /
• 1999

Background : Since dysthymia begins in late childhood or adolescence and has a chronic course, long-term pharmacotherapy may be required. New generation antidepressant, moclobemide, with more acceptable side effect profiles, is effective in the treatment of dysthymia. The main objective of this study was to determine whether they exhibit comparable efficacy and tolerability in dysthymia to amitriptyline. Method and Materials : The efficacy and tolerability of the moclobemide and amitriptyline, were compared in a eight-week single-centre double-blind study in patients(n=37) with dysthymia using he HAMD-17, the Clinical Global Impression Scale(CGI), the Montgomery-Asberg Depression Rating Scale (MADRS), Efficacy Index-Therapeutic Index(EITE), 4-point Index Side Effect Scale(4-PISES), and Efficacy Index- Side Effect Scale(EISE). Results : A total of 37 patients entered the study, 19 were randomly assigned to the moclobemide group and 18 to be amitriptyline group. Demo-graphic and illness characteristics were similar in both groups. There were no significant difference between two groups at the total 17-HDRS score, the HAMD-17% improvement, the total MADRS score, CGI response, and the EITE. In the comparison of EISE between two groups, the scores of the moclobemide group were relatively lower than the amitriptylinen group in full treatment. And the differences were significant(moclobemide group $1.39{\pm}0.61$ ; amitriptyline group $2.00{\pm}0.85$, p<.001). At the 4-PISE, There was no serious or treatment threatening side effects. And there was no specific difference in side effects between two groups. The moclobemide group reported higher EIR scores than the amitriptyline group at every follow up day, but the differences were not significant. And, there was no significant differences in the scores of five HRQOL subcategories which is compared between two groups at every follow up days. Conclusions : In terms of 17-HDRS and MADRS, moclobemide and amitriptyline are equally effective at least in allevating dysthymic symptoms. But moclobemide tended to be less troubling and better tolerated than amitriptyline. Therefore, moclobemide treatment can be used as a safe, and higher satisfactory treatment strategy for the dysthymia.

• 정신신체의학
• /
• 제24권1호
• /
• pp.83-93
• /
• 2016

연구목적 역학연구 우울척도 개정판은 우울 증상을 평가하는 데에 유용성이 입증된 척도로 알려져 있으며 '정신장애의 진단 및 통계 편람 제4판(DSM-IV)'에 기술되어 있는 주요우울장애의 주요한 우울 증상들을 포괄하고 있다. 이 연구에서는 한국판 역학연구 우울척도 개정판을 제작하여 척도의 신뢰도, 타당도와 특성을 평가하고자 하였다. 방 법 DSM-IV의 진단기준에 근거한 MINI를 사용하여 주요우울증, 기분부전증, 달리 분류되지 않는 우울장애로 진단된 48명의 환자군과 48명의 정상 대조군이 연구에 참여하였다. 연구 참여자들은 한국판 역학연구 우울척도 개정판, 몽고메리-아스버그 우울증 평가척도, 우울증 선별척도, 단축형 우울증상 평가 척도, 상태-특성 불안척도를 포함한 척도검사를 시행하여 교차 검증하였다. Cronbach's alpha 계수, Pearson 상관계수, 주성분 분석, Receiver Operating Characteristic(ROC) 곡선, 최적 절단점 산출을 위한 통계분석을 시행하였다. 결 과 한국판 역학연구 우울척도의 Cronbach's alpha 계수는 0.98이었으며, 한국판 역학연구 우울척도 개정판의 총점은 본 연구에서 시행하였던 다른 우울 및 불안척도의 점수와 높은 상관 관계를 보였다. 주성분 분석에서는 두 요인이 전체 분산의 76.29%를 설명하였으며, ROC 곡선을 이용하였을 때, 한국판 역학연구 우울척도 개정판의 최적 절단점은 13점이었다. 결 론 본 연구는 한국판 역학연구 우울척도 개정판의 표준화를 위한 첫 번째 연구로, 한국판 역학연구 우울척도는 우울 증상을 평가하는데 있어 신뢰성 있고, 타당한 척도임을 밝혔다. 또한 이 척도가 진료 및 역학 연구에서 유용한 선별검사 도구로 사용될 수 있을 것으로 기대한다.